[Market Focus] Curacle Rises on Filing for Substance Patent Priority for Alzheimer's Treatment

Curacle is showing strong performance. This appears to be influenced by news that the company has filed for a substance patent priority patent for its Alzheimer's treatment candidate, CU71.

As of 10:42 a.m. on July 11, Curacle was trading at 5,460 won, up 465 won (9.31%) from the previous trading day.

On this day, Curacle announced that it has filed a new patent claiming substance patent priority for CU71, which is being developed as a treatment for Alzheimer's disease.

This patent filing aims to strengthen the scope of rights by adding new compound synthesis and preclinical efficacy data to the substance patent for CU71 filed in July of last year.

CU71 is a first-in-class drug candidate in the vascular endothelial dysfunction inhibitor class, discovered through Curacle's new drug development platform, SOLVADYS, following CU06.

CU71 works by stabilizing the blood-brain barrier (BBB), which has been functionally impaired due to aging, toxic substances, or chronic inflammation, thereby improving cognitive function and protecting neurons.

In particular, BBB dysfunction plays a key pathogenic role in the early stages of neurodegenerative diseases, including Alzheimer's disease. The company explained that CU71 is evaluated to have a mechanistic advantage, as it can be expected to be effective regardless of the drug's brain penetration, by normalizing BBB dysfunction and vascular leakage.

The company emphasized, "While various mechanisms and technological approaches are being attempted in the development of Alzheimer's disease treatments, CU71 is gaining attention as a differentiated therapeutic strategy. Through its mechanism of normalizing BBB dysfunction, which is both a cause and aggravating factor of neurodegenerative diseases, we expect the potential for expanding indications not only to Alzheimer's disease but also to Parkinson's disease and others."